The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Don't forget there is likely to be competition if a bid comes in.
Lovely to see a bidding war.
ROI=ROR
https://novacytinsider.com/novacyt-acquisition-moves/
......so this is the interesting bit.....Novacyt has since fallen into radio silence, shutting down investor queries to the board and redirecting them to FTI Consulting. This follows a similar blackout in spring 2020 when the Group began their partnerships with the government, Astra Zeneca and Glaxo Smith Klein, where all personal Novacyt social media accounts abruptly ceased communications.
Novacyt posted unaudited revenues for FY 2020 of £277 million, with margins around 80%. This windfall is set to continue accruing monthly during the pandemic and will have Dyer and the board hungry to acquire assets in increasingly competitive acquisition conditions.
.....so the partnerships inc NHS are still on 100%... and it's acquisitions to future proof that's on the cards
Van - sincerely hope that a best case scenario does pan out and we get a healthy ROI - but risk is always there and experience tells us all to be wary of a worst case scenario - I know that you will agree . So, any hype (+ve or -ve) is NOT being realistic - for all forum contributors to keep in mind when we get excited, or, despondent. Yes - Vent - it would be logical to think that some competition will ensue - to our benefit is what all retail investors would like to see with any of their investments - GLA DYOR - off to make myself to sit comfortably for the Novacyt webcast. Cheers to you all.
Don't forget there is likely to be competition if a bid comes in.
Lovely to see a bidding war.
''Whomsoever puts a takeover bid in will undoubtably want it a very cheap price''
Not the case at all! These massive potential suitors will likely wait a while to see if the business is sustainable and at what levels. They don't mind waiting and paying more if the company continues to impress and is rock solid!
Whomsoever puts a takeover bid in will undoubtably want it a very cheap price - which is what worries me at this stage - some of the later investors may suffer from this - but an offer could go in at anytime even if NCYT bod doesn't like it - investors have to informed of this, of course. I have seen it so many times that if enough reward/recompense incentive is given to bod members then it becomes [perhaps] too tempting - gets accepted by bod and the retail investors are left with a poor outcome only for the takeover company to reap the [real] rewards. Let's hope that it doesn't happen here. https://www.sharesoc.org [& FCA] have been forewarned of recent sp activity for if evidence is required for review.
I don't think double the price is anywhere near the valuation that would be considered.
It was lass than 30% off that figure before the trading update and our potential is enormous.
I would at least triple the current sp for it to be seriously considered....IMHO.
Double SP today? Lol I doubt a takeover will happen now. Although the cancer side of the diagnostics could be key for AZ to buy as well as covid plays.
If it was taken over the directors k ow the true value. It’s already nearly been Double. Pharma get bought our for crazy high values. NCYT print money and have a lot of cash and no debt
It wouldn’t go for less than 2 billion nowhere near that low so SP 30 pounds of a takeover happens
It’s a big if. I’ve been here 10 months and I’d love it. Just think it would have happened .
Offers will come on for sure or at least enquires. Bird already said they had offers and at the time we’re not interested.
Be nice for to say for double nope.
You maybe right Oriens, - but it is the continual flow of market disruptive products that is the interest.
Winterplex, Exsig direct, and now SNPsig.
The use of the licensed (2012) algorithm from Applied Microarrays, that allows the development of accurate assays in record time was a master stroke :)
B2h......gm said last March, or it might of been early April, in an interview with the Times, that he been approached non formally.
At every stage in the introduction of the 12+ new products introduced in the last year, we have had little notice of what to expect mostly.
There is a grand plan being enacted and orchestrated by GM, and he stated at the end of the AGM last year,
we are only at the start of the journey.
So GM knows what this company is currently worth TO HIM.
When he's done, he knows what it will be worth TO HIM.
He will know if an offer is good or not, and I trust him to only be satisfied with an out of this world offer, that he has negotiated.
With all these market disruptive products that keep emerging, I would be surprised if he has not refused quite a few offers.
That is why I think this company will not be sold yet.
If he has to fight a hostile takeover, I trust him to do so on his terms, he seems to know what he's doing.
It could be, there would be willing buyers but probably not willing sellers as the Board & their expertise is key to the value. IMO, (often wrong) they won't want out of a situation where they have so much effect so they might perhaps consider some arrangement if brought some functional benefit or enhancement to their own capacity to deliver what they feel is needed.
Market cap now around 500 million .This is peanuts.Around 150 million cash.it will be taken over in the next few weeks at least double todays price